SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 57.39-0.6%4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Tadsamillionaire12/20/2006 12:19:34 PM
   of 347
 
ACP Observer Publishes Letter on GenoMed's Ability to Prevent Most Kidney Failure
GenoMed(TM) (Pink Sheets:GMED), a Next Generation Disease Management company, announced today that ACP Observer, the monthly news magazine for doctors of internal medicine published by the American College of Physicians, included a letter in its December issue referring to GenoMed's ability to prevent potentially most kidney failure in the US.

The letter, entitled "Promoting Dialysis Alternative" (http://www.acponline.org/journals/news/dec06/letters.htm), was written by GenoMed's CEO, Dr. David Moskowitz, who is a Fellow of the American College of Physicians. The letter calls the medical community to task for the four years of "organizational silence" since Dr. Moskowitz's paper on kidney failure was first published in a peer-reviewed medical journal.

Dr. Moskowitz's paper, published in 2002, described a novel treatment approach using already existing medications but at a higher dose. If begun early enough, this approach could reverse kidney failure in white and black patients with diabetes and high blood pressure. These two diseases cause 90% of kidney failure in the US.

The Centers for Medicaid and Medicare (CMS) currently pay about $25 billion annually for kidney dialysis and transplantation. When Dr. Moskowitz briefed CMS about his paper in 2004, the Medical Director and his staff at CMS referred Dr. Moskowitz to the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Neither the NIDDK, CMS, nor any non-profit kidney association had any interest.

Publication of Dr. Moskowitz's letter in ACP Observer is the first time that a mainstream medical news magazine has carried the story.

Said Dr. Moskowitz, "In medical school, we were encouraged to find cures. I wouldn't have believed it if somebody had told me then that there was no point in finding any cures because news of the cure would just be suppressed. Yet that is exactly what has happened for the past four years."

Dr. Moskowitz continued, "Medicine, like any human endeavor, thrives on the status quo, and hates change. In the 1950s, nobody thought twice about putting polio wards and TB sanitaria out of business. But potentially eliminating 90% of a $25 billion a year industry is another thing altogether. Nowadays, nobody wants their budget cut."

Added Dr. Moskowitz, "The American College of Physicians has long been the most prestigious organization in the United States for internists. I've always been extremely proud to belong to it. I'm especially grateful for its courage in breaking the silence that has surrounded my paper for the past four years."

About GenoMed
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext